363
Participants
Start Date
January 31, 2002
Primary Completion Date
April 30, 2007
Study Completion Date
April 30, 2007
thalidomide
tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
placebo
100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
Department of Haematology, St. Olavs hospital/NTNU, Trondheim
The Research Council of Norway
OTHER
Nordic Myeloma Study Group, Germany
UNKNOWN
Norwegian University of Science and Technology
OTHER